Phio Pharmaceuticals Corp (PHIO)


Stock Price Forecast

Feb. 21, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Phio Pharmaceuticals Corp chart...

About the Company

Phio Pharmaceuticals Corp. is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYLâ„¢) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor micro-environment. Our goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities.

Employees

10

CEO

Gerrit Dispersyn

Exchange

NASDAQ

Website

phiopharma.com

$0M

Total Revenue

10

Employees

$10M

Market Capitalization

-0.79

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $PHIO News

Phio Pharmaceuticals Corp. (PHIO)

1d ago, source: Yahoo Finance

*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...

Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies

1mon ago, source: Nasdaq

About Phio Pharmaceuticals Corp. Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYLâ„¢ RNAi technology is designed to make immune cells ...

Phio Pharmaceuticals expands clinical trial sites for cancer study

5d ago, source: Investing

MARLBOROUGH, Mass. - Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a biotechnology company focused on immuno-oncology, has announced the addition of three new clinical trial sites for its Phase 1b ...

Phio secures patent for skin disorder treatments

12d ago, source: Investing

MARLBOROUGH, Mass. - Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company, has been granted a U.S. patent for two compounds, RXI-185 and RXI-231, designed to address ...

Phio Pharmaceuticals expands clinical trial sites for cancer study

5d ago, source: Investing

MARLBOROUGH, Mass. - Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a biotechnology company focused on immuno-oncology, has announced the addition of three new clinical trial sites for its Phase 1b study ...

Phio Pharmaceuticals Corp PHIO

3d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Phio Pharmaceuticals Corp

1mon ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Phio Pharmaceuticals Corp.

19d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...